Thc Cbd
Thc Cbd - Related Videos
07:51
Administration of Δ9-Tetrahydrocannabinol (THC) in Adolescent and Adult Mice
0 Views •
2025
Δ9-tetrahydrocannabinol (THC) is the intoxicating constituent in cannabis and a controlled substance in the United States. This article outlines standard procedures for obtaining, storing, and administering THC to mice complying with current legal regulations and briefly introduces a method to assess basic pharmacodynamic effects of THC in rodents.
04:32
Biliary System Resin Casting: A Technique for Analyzing 3D Architecture of Biliary System in Murine Model Using Radiopaque Resin Injection
0 Views •
2025
This video describes the procedure for biliary system resin casting, for understanding 3D biliary architecture. This technique provides insights into the internal diameter and network connectivity of the biliary system, which could be used for liver regeneration analysis.
09:01
Intravital Microscopy and Thrombus Induction in the Earlobe of a Hairless Mouse
0 Views •
Cited by 4 •
2017
The ear model of the hairless SKH1-Hrhr mouse enables intravital fluorescence microscopy of microcirculation and phototoxic thrombus induction without prior surgical preparation in the examined microvascular bed. Therefore, the ear of the hairless mouse is an excellent in vivo model to study the complex interactions during microvascular thrombus formation, thrombus evolution, and thrombolysis.
FAQs
The main mechanistic contrast is THC’s primary activation of CB1 receptors in the central nervous system versus CBD’s limited direct activity at those receptors. CBD instead influences cannabinoid-related and other signaling pathways. This difference helps explain why the compounds can have distinct effects and why they are evaluated separately in medical research and treatment formulations.
CB1 receptor activity is important because it links THC to psychoactive effects through signaling in the central nervous system. CBD does not show the same primary direct activity at CB1 receptors, so its effects are characterized through broader signaling influences. Understanding this distinction helps clinicians and researchers interpret potential benefits, adverse effects, and treatment responses.
Outcomes depend on more than the cannabinoid selected. Dosing, adverse effects, drug interactions, and regulatory status all influence how THC- or CBD-containing formulations are evaluated. These variables make careful clinical assessment essential, particularly when determining whether a formulation is appropriate for a specific condition or how its potential benefits compare with possible risks.
Clinical use should involve selecting an appropriate formulation, applying careful dosing, and evaluating the patient’s response and risks. Assessment should account for the intended condition, possible adverse effects, drug interactions, and the relevant regulatory status. This structured approach supports safer decisions when these compounds are considered for treatment-related symptoms or selected medical disorders.
Medical research and selected formulations address several areas, including treatment-related nausea, pain, muscle spasticity, and certain seizure disorders. The compounds are not interchangeable across these applications because their mechanisms, benefits, and adverse effects differ. Clinical evaluation is therefore needed to determine whether a particular formulation is relevant to the condition being treated.
Potential benefits must be considered alongside adverse effects and drug interactions for both compounds. These safety factors can influence formulation choice, dosing decisions, and whether treatment is clinically appropriate. Regulatory status adds another layer of context, so medical use requires individualized evaluation rather than assuming that evidence or experience with one cannabinoid automatically applies to the other.